M&A / Deals Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact Pharmaceutical TechnologyEli Lilly and Profluent will harness AI to discover and develop recombinases for precise, large-scale gene editing.Read full story pharminent April 29, 2026 (Last updated: April 29, 2026) Pharmaceutical Technology Eli Lilly and Profluent will harness AI to discover and develop recombinases for precise, large-scale gene editing. Read full story Post navigation Previous: The strategic investments expanding CDMO capabilities for HPAPIs and ADCsNext: Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’ Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
